A Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Latest Information Update: 09 Mar 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 05 Mar 2025 Planned End Date changed from 16 Jun 2026 to 16 Jun 2028.
- 05 Mar 2025 Planned primary completion date changed from 16 Jun 2025 to 16 Jun 2028.
- 05 Mar 2025 Status changed from suspended to recruiting.